When Statins Do Not Adequately Lower LDL-C: Novel Therapies to Improve Outcomes in Patients with HeFH and ASCVD


James Underberg MD, FACP, MNLA

Clinical Assistant Professor of Medicine

New York University School of Medicine, NYU Center for the Prevention of Cardiovascular Disease, New York, NY
Director, Bellevue Hospital Lipid Clinic, New York, NY
Past-President, National Lipid Association, Jacksonville, FL
President, American Board Clinical Lipidology

Erin D. Michos, MD, MHS

Associate Director of Preventive Cardiology

Division of Cardiology

Johns Hopkins University School of Medicine

Co-Editor in Chief of the American Journal of Preventive Cardiology

Program Overview

Since the release of the 2018 Cholesterol Guideline, new lipid-lowering medications have been approved by the Food and Drug Administration (FDA). This program is designed to improve clinicians’ knowledge about the collection of available cholesterol-lowering medications and how to utilize them to narrow the treatment gap and improve outcomes in patients with HeFH and ASCVD.

Target Audience

This educational initiative is designed for specialty physicians, nurse practitioners (NPs), and physician assistants (PAs) interested in the diagnosis and treatment of hypercholesterolemia.


Failure to Achieve Target Goals

Credit Amount: 0.25

Credit Type: CME

Expiration: January 11, 2024


Statin Intolerance and Therapy Selection

Credit Amount: 0.25

Credit Type: CME

Expiration: January 18, 2024

This activity is jointly provided by Global Education Group and Iridium Continuing Education.
This educational activity is supported by an independent educational grant from Novartis Pharmaceuticals.